

CBR4 RABBIT PAB

Cat.#: S218200

Product Name: Anti-CBR4 Rabbit Polyclonal Antibody

Synonyms: SDR45C1

UNIPROT ID: Q8N4T8 (Gene Accession - BC033650)

Background: Enables several functions, including 3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activity; NADPH binding activity; and NADPH dehydrogenase (quinone) activity. Involved in fatty acid biosynthetic process; glycoside metabolic process; and protein tetramerization. Located in mitochondrial matrix. Part of oxidoreductase complex.

Immunogen: Fusion protein of human CBR4

Applications: ELISA, WB, IHC

Recommended Dilutions: IHC: 50-200;WB: 1000-5000;ELISA: 5000-10000

Host Species: Rabbit

Clonality: Rabbit Polyclonal

Isotype: Immunogen-specific rabbit IgG


Purification: Antigen affinity purification

Species Reactivity: Human, Mouse, Rat

Constituents: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol


Research Areas: Metabolism

Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 218200(CBR4 Antibody) at a dilution of 1/80(Cytoplasm).


☒ In comparison with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the fusion protein and then with 218200(Anti-CBR4 Antibody) at dilution 1/80.



The image on the left is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using 218200(Anti-CBR4 Antibody) at a dilution of 1/80.



In comparison with the IHC on the left, the same paraffin-embedded Human prostate cancer tissue is first treated with fusion protein and then with D223928(Anti-CBR4 Antibody) at dilution 1/80.



Gel: 12%SDS-PAGE, Lysate: 40 µg;
 Lane 1-2: Raji cell, Mouse liver tissue lysates;
 Primary antibody: 218200(CBR4 Antibody) at dilution 1/1300;
 Secondary antibody: HRP-conjugated Goat anti rabbit IgG at 1/5000 dilution;
 Exposure time: 20 seconds



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
